This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mizukami, Y. Articles by Chung, D. C. Search for Related Content PubMed PubMed Citation Articles by Mizukami, Y. Articles by Chung, D. C.

Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis

Authors' Affiliations: ¹ Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan and ² Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts

Requests for reprints: Yusuke Mizukami, Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College, 2-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan. Phone: 81-166-68-2462; Fax: 81-166-68-2469; E-mail: mizu{at}asahikawa-med.ac.jp.

Abstract

Among the factors that can stimulate angiogenesis, vascular endothelial growth factor has emerged as one of the most important, and inhibition of vascular endothelial growth factor has recently shown efficacy in the treatment of advanced colorectal cancer. Hypoxia develops within solid tumors and is one of the most potent stimuli of vascular endothelial growth factor expression. This effect is mediated primarily by hypoxia inducible factor-1 (HIF-1), often considered a master regulator of angiogenesis in hypoxia. Consequently, inhibition of HIF-1 has been proposed as a strategy to block tumor angiogenesis therapeutically. However, accumulating evidence indicates that HIF-independent pathways can also control angiogenesis. This review highlights some of the key signaling pathways independent of HIF-1 that can stimulate angiogenesis in hypoxia. Understanding the full spectrum of molecular pathways that control tumor angiogenesis is critical for the optimal design of targeted therapies.

This article has been cited by other articles:

				K. J. Langen and S. M. Eschmann Correlative Imaging of Hypoxia and Angiogenesis in Oncology J. Nucl. Med., April 1, 2008; 49(4): 515 - 516. [Full Text] [PDF]

				M. Picchio, R. Beck, R. Haubner, S. Seidl, H.-J. Machulla, T. D. Johnson, H.-J. Wester, G. Reischl, M. Schwaiger, and M. Piert Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography J. Nucl. Med., April 1, 2008; 49(4): 597 - 605. [Abstract] [Full Text] [PDF]